Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06817018 · ClinicalTrials.gov registry record · Phase 2
Ginger Root Extract for Sciatic Pain Individuals
A Phase 2 study of Neuropathic Pain and Sciatic Pain, sponsored by Leslie Shen.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 2
- Study locations
NCT06817018: Recruiting Phase 2 study of Neuropathic Pain and Sciatic Pain, sponsored by Leslie Shen.
NCT06817018 is a Phase 2 study of Neuropathic Pain and Sciatic Pain that is actively recruiting participants, run by Leslie Shen. The registered enrollment target is 80 participants, below the 99-participant average among 35 other Neuropathic Pain trials with a reported enrollment target (19% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06817018, a Phase 2 study of Neuropathic Pain and Sciatic Pain, is actively recruiting participants, sponsored by Leslie Shen.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 2
- Study locations
Study Summary
Neuropathic pain affects the quality of life of many Americans. Non-pharmacological strategies such as bioactive compounds in foods are being explored as therapeutics but can also serve as tools to better understand pain mechanisms. The previous study reported that ginger root extract supplementation palliated pain-spectrum behaviors in animals with neuropathic pain via the microbiota-gut-brain axis. The proposed study is primarily designed to use ginger supplementation for a better understanding of the role of microbiota-gut-brain interactions in sciatica states in a randomized, double-blinded, and placebo-controlled trial. Eighty participants with sciatica will be randomized to receive placebo (2000 mg starch daily) or ginger (2000 mg daily) for 8 weeks. This study will evaluate the effects of ginger supplementation on gut function measured as gut microbiota composition using 16S rRNA sequencing analysis, intestinal permeability based on plasma lipopolysaccharide binding protein and fecal zonulin using ELISA, and fecal metabolites using LC-MS/MS analysis (SA 1); on neuroinflammation in whole blood mRNA using nCounter® Neuroinflammation Panels analysis (SA 2); and on pain-associated outcomes and brain neuroplasticity by assessing functional (resting state-fMRI) and structural (Diffusion Tensor Imaging) connectivity (SA 3).
Primary Outcome
Intestinal permeability biomarker
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DRUG Ginger
Study Locations (2)
Texas
- Texas Tech University Health Sciences Center - Lubbock
- Texas Tech University Health Sciences Center - Lubbock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-07-01 |
| Est. Completion | 2028-02-28 |
| Phase | Phase 2 |
What NCT06817018 shows while recruiting
NCT06817018 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 99-participant average among 35 other Neuropathic Pain trials with a reported enrollment target (19% lower).
The record links to 2 conditions, with Neuropathic Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06817018 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06817018 about?
NCT06817018 is a clinical study titled "Ginger Root Extract for Sciatic Pain Individuals". Neuropathic pain affects the quality of life of many Americans. Non-pharmacological strategies such as bioactive compounds in foods are being explored as therapeutics but can also serve as tools to better understand pain mechanisms. The previous study reported that ginger root extract supplementatio...
What is the current status of trial NCT06817018?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2025-07-01. Estimated completion is 2028-02-28.
What conditions does trial NCT06817018 study?
This clinical trial studies the following conditions: Neuropathic Pain, Sciatic Pain.
What interventions are being tested in trial NCT06817018?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Ginger (DRUG).
Who is sponsoring clinical trial NCT06817018?
This trial is sponsored by Leslie Shen, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06817018 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuropathic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06817018's enrollment target sits among peer trials
80 10th of 35 higher than 26 of 35 other Neuropathic Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuropathic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Vitamin D Supplementation on Reported Rates of Taxane-Induced Neuropathy
RECRUITING · Phase 2
-
Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain
RECRUITING · Phase 2
-
Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy
ACTIVE NOT RECRUITING · Phase 2
-
Therapeutic Interventions For Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL)
COMPLETED · Phase 2
-
The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain
COMPLETED · Phase 2
-
BMS-741672 for Diabetic Neuropathic Pain
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI